Expressão estável de distrofina em camundongos com distrofia muscular tratados com células satélites musculares corrigidas em laboratório com oligonucleotídeos
USA – os autores já tinham demonstrado que em cultura de células de distrofia muscular os oligonucleotídeos tinham a capacidade corrigir o defeito genético. Nesta pesquisa as células satélites musculares corrigidas em laboratório foram injetadas em camundongos com distrofia muscular. Os resultados mostraram a expressão progressiva da distrofina e melhora das alterações patológicas musculares. O método se mostrou viável e permitiria corrigir as células do próprio paciente, evitando reações imunológicas.
O resumo em inglês pode ser lido abaixo:
(Stem Cells, 2014;32(7): 1817-30) Ex Vivo Gene Editing of the Dystrophin Gene in Muscle Stem Cells Mediated by Peptide Nucleic Acid Single Stranded Oligodeoxynucleotides Induces Stable Expression of Dystrophin in a Mouse Model for Duchenne Muscular Dystrophy
Farnoosh Nik-Ahd and Carmen Bertoni – USA
Duchenne muscular dystrophy (DMD) is a fatal disease caused by mutations in the dystrophin gene, which result in the complete absence of dystrophin protein throughout the body. Gene correction strategies hold promise to treating DMD. Our laboratory has previously demonstrated the ability of peptide nucleic acid single-stranded oligodeoxynucleotides (PNA-ssODNs) to permanently correct single-point mutations at the genomic level. In this study, we show that PNA-ssODNs can target and correct muscle satellite cells (SCs), a population of stem cells capable of self-renewing and differentiating into muscle fibers. When transplanted into skeletal muscles, SCs transfected with correcting PNA-ssODNs were able to engraft and to restore dystrophin expression. The number of dystrophin-positive fibers was shown to significantly increase over time. Expression was confirmed to be the result of the activation of a subpopulation of SCs that had undergone repair as demonstrated by immunofluorescence analyses of engrafted muscles using antibodies specific to full-length dystrophin transcripts and by genomic DNA analysis of dystrophin-positive fibers. Furthermore, the increase in dystrophin expression detected over time resulted in a significant improvement in muscle morphology. The ability of transplanted cells to return into quiescence and to activate upon demand was confirmed in all engrafted muscles following injury. These results demonstrate the feasibility of using gene editing strategies to target and correct SCs and further establish the therapeutic potential of this approach to permanently restore dystrophin expression into muscle of DMD patients.
